Jupiter Neurosciences (JUNS) to Announce Quarterly Earnings on Wednesday

Jupiter Neurosciences (NASDAQ:JUNS) is projected to release its results before the market opens on Wednesday, September 2nd. Analysts expect the company to post earnings of ($3.75) per share and revenue of $0.40 million for the quarter.

Jupiter Neurosciences (NASDAQ:JUNS) last announced its earnings results on Friday, August 14th. The company reported ($5.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.75) by ($1.31). The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.40 million.

Jupiter Neurosciences Price Performance

NASDAQ:JUNS opened at $4.18 on Monday. The stock has a market cap of $3.82 million, a P/E ratio of -0.22 and a beta of 1.98. The company has a fifty day moving average price of $10.45 and a 200 day moving average price of $22.14. Jupiter Neurosciences has a one year low of $4.10 and a one year high of $137.96.

Analyst Ratings Changes

A number of brokerages have recently commented on JUNS. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jupiter Neurosciences in a research report on Wednesday, June 24th. Wall Street Zen upgraded Jupiter Neurosciences from a “strong sell” rating to a “sell” rating in a research note on Sunday, August 16th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Investors Weigh In On Jupiter Neurosciences

A hedge fund recently raised its position in Jupiter Neurosciences stock. Geode Capital Management LLC increased its stake in shares of Jupiter Neurosciences, Inc. (NASDAQ:JUNS) by 27.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 132,641 shares of the company’s stock after buying an additional 28,826 shares during the quarter. Geode Capital Management LLC owned 0.39% of Jupiter Neurosciences worth $135,000 at the end of the most recent reporting period.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.